Advertisement
Preclinical data from Alligator demonstrate strong anti-tumor effects

The company will present these preclinical data for the drug candidate ATOR-1017 at the 4th Annual Immuno-oncology Summit Europe, to be held in London on March 18-22, 2019.
ATOR-1017 is a monoclonal antibody in development for the treatment of metastasizing cancer. It activates the co-stimulatory receptor 4-1BB and its immuno-stimulatory function is dependent on cross-linking to Fc-gamma receptors on immune cells.
Experimental model for colon cancer
The new data show that ATOR-1017, in an experimental model for colon cancer (MC38), displays potent anti-tumor effects. Furthermore, ATOR-1017 induces a dose-dependent effect on tumor growth inhibition and survival. Existing preclinical data have already shown that ATOR-1017 stimulates both NK (Natural Killer) and T cells, both of which contribute to an effective immune-mediated killing of tumor cells.
“ATOR-1017 is designed to have a superior safety and efficacy profile through its tumor-directed properties and these latest data support the positioning of ATOR-1017 as a best-in-class 4-1BB antibody with the potential to reduce side effects, but also to generate a potent and long-lasting immune response. This provide us with a strong preclinical package to move into the next phase of development. We expect to start clinical trials in cancer patients later this year,” said Christina Furebring, SVP Preclinical Development, at Alligator Bioscience.
Photo of Christina Furebring: Alligator Bioscience
Published: March 19, 2019